Caricamento...
Clinical validation study of circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib
BACKGROUND: Melanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, there have been no large studies examining the association...
Salvato in:
| Pubblicato in: | Lancet Oncol |
|---|---|
| Autori principali: | , , , , , , , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8034833/ https://ncbi.nlm.nih.gov/pubmed/33587894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(20)30726-9 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|